(702) 683-8946

Monday - Friday 9am to 5pm

triangle
ad1

http://crweworld.com/assets/images/ad/content-delivery-solution.jpg

Our content delivery solution through CRWE WORLDCRWE Press Release and CRWE Tubegives corporations and businesses a vehicle to expand their exposure

Content Delivery Solution (Learn More)

ad3

https://crweworld.com/assets/img/crwe_info.png

CRWE Info ( CRWE.Info ) provides news and updates about Crown Equity Holdings Inc. and the CRWE World platform

www.crwe.info

ad4

https://crweworld.com/assets/images/ad/submit_a_press_release.jpg

Submit Your Press Release/News to the CRWE WORLD Network for $14.95! Increase Visibility, Boost Your Business

www.CRWEPressRelease.com






Latest News Releases From The Newsroom

Citigroup Initiates Coverage on Major Investment Firms: Insights on BlackRock, Blackstone, Blue Owl, KKR & Co, and Carlyle Group

May 19th, 2023

Citigroup has initiated coverage on several major investment firms with favorable recommendations and price targets. BlackRock Inc. (NYSE: BLK) has been initiated with a Buy rating and a price target of $750. In pre-market trading, the stock is cu. Read more

Flowers Foods Adjusts Outlook, Cavco Industries Surpasses Expectations, OncoSec Medical Closes Offering

May 18th, 2023

Flowers Foods, Inc. (NYSE: FLO) has reported adjusted earnings per share (EPS) of $0.38 for the first quarter of fiscal 2023, meeting the consensus estimate. However, due to a slow start to the year and lower-than-expected branded retail sales result. Read more

Ross Stores Exceeds Q1 Expectations, Pfizer's RSV Vaccine Candidate Gains FDA Committee Support, Lucy Scientific Partners with TheraPsil for Psilocybin Access

May 18th, 2023

Ross Stores, Inc. (Nasdaq: ROST) has reported first-quarter fiscal 2023 earnings per share (EPS) of $1.09, surpassing the consensus estimate of $1.06. However, in after-hours trading, $ROST is experiencing a slight decline, currently trading at $105.. Read more

Financial Snapshot: Farfetch Surpasses Expectations, DXC Technology Faces After-Hours Decline, Globant Falls Short, Applied Materials Exceeds Estimates

May 18th, 2023

In the latest financial reports, Farfetch Limited (NYSE: FTCH) announced an adjusted loss of $0.16 per share for the first quarter of 2023, surpassing the consensus estimate of a loss of $0.42 per share. As a result, $FTCH's after-hours trading shows. Read more

FTC Warns About Misuses of Biometric Information and Harm to Consumers

May 18th, 2023

Agency issues policy statement addressing emerging technologies that might harm consumers and violate the FTC Act Washington D.C. / CRWE PRESS RELEASE / May 18, 2023 - The Federal Trade Commission today issued a warning that the increasi. Read more

FTC Proposes Amendments to Strengthen and Modernize the Health Breach Notification Rule

May 18th, 2023

Proposed changes would underscore the rule’s applicability to health apps and other evolving technologies Washington D.C. / CRWE PRESS RELEASE / May 18, 2023 - The Federal Trade Commission is seeking comment on proposed changes to . Read more

Major Advancements in Biotech: Enveric Biosciences' Psilocin Prodrug Patent Allowance, Phio Pharma's Breakthrough in Cancer Therapy, and Teva's Strategic Framework

May 18th, 2023

Enveric Biosciences, Inc. (Nasdaq: ENVB) has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for a patent application related to their new chemical entity (NCE) psilocin prodrug, known as EB-373. This prodrug. Read more

Monro Falls Short of Q4 Expectations as Micron Technology, Mullen Automotive, and FibroGen Make Positive Pre-Market Moves

May 18th, 2023

Monro, Inc. (Nasdaq: MNRO) has released its financial results for the fourth quarter of fiscal 2023, reporting adjusted earnings per share (EPS) that fell short of market expectations. The company's adjusted EPS for the quarter stood at $0.08, compar. Read more

Initiated with a Buy: Arcellx, Pliant Therapeutics, Tarsus Pharmaceuticals, Varonis Systems

May 18th, 2023

Several companies have recently received initiations with Buy ratings from prominent financial institutions, indicating positive outlooks for their future performance. Arcellx, Inc. (Nasdaq: ACLX) has been initiated with a Buy rating and a price t. Read more

EyePoint Pharma's YUTIQ Sale, Protalix's Milestone Achievement, and Walmart's Q1 Surpass Expectations: Pre-Market Update

May 18th, 2023

EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT) has announced a definitive agreement for the sale of YUTIQ, their fluocinolone acetonide intravitreal implant used in the treatment of chronic non-infectious uveitis affecting the posterior segment of the. Read more